Development of new drugs is a drawn-out, risky process that often takes more than a decade to pan out. Reasons can be many, including strict approval requirements, fragmented analytical methods, and more.
By generating reads of native DNA and RNA molecules, Oxford Nanopore sequencing provides all required data in a single end-to-end workflow. It combines multiple data types into a single experiment and eliminates the need for chemical conversion.
This guide introduces Oxford Nanopore sequencing solutions which cover everything from the identification of biomarkers to final product quality control. It also tries to answer the most pressing questions in drug development:
- Which end-to-end workflows are designed for biopharma applications.
- The full portfolio of Oxford Nanopore sequencing devices that can deliver multiomic insights
- Real-world case studies highlighting how Oxford Nanopore sequencing supports the drug development pipeline.
